Rinvoq (Upadacitinib) for Spondylitis | MySpondylitisTeam

Connect with others who understand.

sign up Log in
About MySpondylitisTeam
Powered By

Rinvoq is a prescription medication approved by the U.S. Food and Drug Administration (FDA) for treating ankylosing spondylitis or nonradiographic axial spondyloarthritis in adults 18 years and older who have not responded to treatment with tumor necrosis factor (TNF) inhibitors. Rinvoq is also known by its drug name, upadacitinib.

Rinvoq is a Janus kinase inhibitor. Rinvoq is believed to work by blocking Janus kinase enzymes which lead to inflammation for people with spondyloarthritis.

How do I take it?
Rinvoq is taken once a day. Rinvoq comes in extended-release tablet form.

Side effects
The FDA-approved label for Rinvoq lists common side effects including upper respiratory infections, shingles, fever, nausea, acne, headache, and cough.

Rare but serious side effects listed for Rinvoq can include life-threatening infections, blood clots, liver problems, lymphomas, tuberculosis, and fetal harm in pregnant people.

For more details about this treatment, visit:

Rinvoq — AbbVie

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in